NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY JP Morgan January 2021 Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the advancement of our clinical trials, patient enrollments in our existing and planned clinical ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer inc ...

() Replimune NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC August 2020 Safe harbor Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the advancement of our clinical trials, patient enrollments in our existing and planned clinical trials and th ...

(Exact name of registrant as specified in its charter) For the transition period from to Commission file number 001-38596 REPLIMUNE GROUP, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of (I.R.S. Employer incorpor ...

Use these links to rapidly review the document TABLE OF CONTENTS REPLIMUNE GROUP, INC. Financial Statements For the Years Ended March 31, 2020, 2019 and 2018 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I. ...

Replimune's Immulytic Platform - The platform is designed to maximally activate the immune system against a patient's cancer, aiming to establish Replimune's products as the second cornerstone of immuno-oncology[4] - RP1 is in multiple clinical trials, focusing on immuno-responsive tumors, with potential registration clinical trials underway or to initiate in the first half of the year[4] - RP2 & RP3 are intended to treat less immuno-responsive tumors, with RP3 expected to enter the clinic in 2020[4] - The company had approximately $183 million in cash as of December 31, ensuring they are well-capitalized to deliver on their plans[4] Clinical Data and Trials - A randomized controlled phase 2 study of T-VEC + ipilimumab vs ipilimumab alone in advanced melanoma showed more than doubled response rates in combination (38% vs 18%)[14] - A T-VEC+pembrolizumab ph1b study showed a 67% response rate and a 43% CR rate[14] - A registration-directed randomized controlled Phase 2 trial in CSCC involves 240 patients randomized 2:1 (RP1+ cemiplimab vs cemiplimab alone)[24] - A 30 patient clinical trial of single agent RP1 is being conducted in solid organ transplant recipients with CSCC[24] - Approximately half of advanced melanoma patients still die of their disease, despite multiple approved therapies, leading to a focus on patients with primary resistance to anti-PD1 therapy[26] Manufacturing and Future Plans - The company has leased a 63,000 ft2 manufacturing facility in Framingham, MA, expected to be online to produce clinical product in 2020[58] - ~$183 million in cash at December 31, 2019 will be sufficient to fund its operating expenses into the 2H 2022[60]

NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY December 2019 Piper Jaffray 31st Annual Healthcare Conference Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about our use of cash, our advancement o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38596 REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I ...

NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY SITC Investor Event Presentation November 8th 2019 Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forwardlooking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about our use of cash, our advancement of our clinic ...